Terconazole Vaginal Cream 0.8%

Terconazole


A-s Medication Solutions
Human Prescription Drug
NDC 50090-6299
Terconazole Vaginal Cream 0.8% also known as Terconazole is a human prescription drug labeled by 'A-s Medication Solutions'. National Drug Code (NDC) number for Terconazole Vaginal Cream 0.8% is 50090-6299. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Terconazole Vaginal Cream 0.8% drug includes Terconazole - 8 mg/g . The currest status of Terconazole Vaginal Cream 0.8% drug is Active.

Drug Information:

Drug NDC: 50090-6299
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Terconazole Vaginal Cream 0.8%
Also known as the trade name. It is the name of the product chosen by the labeler.
Proprietary Name Base: Terconazole
The base of the Brand/Proprietary name excluding its suffix.
Proprietary Name Suffix: Vaginal Cream 0.8%
A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Terconazole
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: A-s Medication Solutions
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:TERCONAZOLE - 8 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:VAGINAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Feb, 2005
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 27 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA021735
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
UNII:
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Azole Antifungal [EPC]
Azoles [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
50090-6299-020 g in 1 TUBE, WITH APPLICATOR (50090-6299-0)29 Dec, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Terconazole vaginal cream 0.8% terconazole terconazole terconazole butylated hydroxyanisole cetyl alcohol isopropyl myristate polysorbate 60 polysorbate 80 propylene glycol stearyl alcohol water

Drug Interactions:

Drug interactions: the therapeutic effect of this product is not affected by oral contraceptive usage.

Indications and Usage:

Indications and usage terconazole vaginal cream 0.8% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). as terconazole vaginal cream 0.8% is effective only for vulvovaginitis caused by the genus candida, the diagnosis should be confirmed by koh smears and/or cultures.

Warnings:

Warnings none.

General Precautions:

General: discontinue use and do not retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during use.

Dosage and Administration:

Dosage and administration one full applicatorful (5 g) of terconazole vaginal cream 0.8% (40 mg terconazole) should be administered intravaginally once daily at bedtime for three consecutive days. before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. the therapeutic effect of terconazole vaginal cream 0.8% is not affected by menstruation.

Contraindications:

Contraindications patients known to be hypersensitive to terconazole or to any of the components of the cream.

Adverse Reactions:

Adverse reactions during controlled clinical studies conducted in the united states, patients with vulvovaginal candidiasis were treated with terconazole vaginal cream 0.8% for 3 days. based on comparative analyses with placebo and a standard agent, the adverse experiences considered most likely related to terconazole vaginal cream 0.8% were headache (21% vs 16% with placebo) and dysmenorrhea (6% vs 2% with placebo). genital complaints in general, and burning and itching in particular, occurred less frequently in the terconazole vaginal cream 0.8% 3 day regimen (5% vs. 6%-9% with placebo). other adverse experiences reported with terconazole vaginal cream 0.8% were abdominal pain (3.4% vs. 1% with placebo) and fever (1% vs. 0.3% with placebo). the therapy-related dropout rate was 2.0% for the terconazole vaginal cream 0.8%. the adverse drug experience most frequently causing discontinuation of therapy was vulvovaginal itching, 0.7% with the terconazole vaginal cream 0.8% group and 0.3%
with the placebo group.

Drug Interactions:

Drug interactions: the therapeutic effect of this product is not affected by oral contraceptive usage.

Pediatric Use:

Pediatric use: safety and efficacy in children have not been established.

Geriatric Use:

Geriatric use: clinical studies of terconazole vaginal cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Overdosage:

Overdosage overdosage of terconazole in humans has not been reported to date. in the rat, the oral ld 50 values were found to be 1741 and 849 mg/kg for the male and female, respectively. the oral ld 50 values for the male and female dog were ≈1280 and ≥640 mg/kg, respectively.

Description:

Description terconazole vaginal cream 0.8% is a white to off-white, water washable cream for intravaginal administration containing 0.8% of the antifungal agent terconazole, cis -1-[ p -[[2-(2,4-dichlorophenyl)-2-(1 h -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine, compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, stearyl alcohol, and purified water. the structural formula of terconazole is as follows: terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. it is insoluble in water; sparingly soluble in ethanol; and soluble in butanol. structuralformula

Clinical Pharmacology:

Clinical pharmacology following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations. following daily intravaginal administration of 0.8% terconazole 40 mg (0.8% cream x 5 g) for seven days to normal humans, plasma concentrations were low and gradually rose to a daily peak (mean of 5.9 ng/ml or 0.006 mcg/ml) at 6.6 hours. results from similar studies in patients with vulvovaginal candidiasis indicate that the slow rate of absorption, the lack of accumulation, and the mean peak plasma concentration of terconazole was not different from that observed in healthy women. the absorption characteristics of terconazole 0.8% in pregnant or non-pregnant patients with vulvovaginal candidiasis were also similar to those found in normal volunteers. following oral (30 mg) administration of 14 c-labelled terconazole, the harmonic half-life of elimination from the blood fo
r the parent terconazole was 6.9 hours (range 4.0-11.3). terconazole is extensively metabolized; the plasma auc for terconazole compared to the auc for total radioactivity was 0.6%. total radioactivity was eliminated from the blood with a harmonic half-life of 52.2 hours (range 44-60). excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes. in vitro , terconazole is highly protein bound (94.9%) and the degree of binding is independent of drug concentration. photosensitivity reactions were observed in some normal volunteers following repeated dermal application of terconazole 2.0% and 0.8% creams under conditions of filtered artificial ultraviolet light. photosensitivity reactions have not been observed in u.s. and foreign clinical trials in patients who were treated with terconazole suppositories or vaginal cream 0.8%. microbiology: terconazole exhibits fungicidal activity in vitro against candida albicans . antifungal activity also has been demonstrated against other fungi. the mic values of terconazole against most lactobacillus spp. typically found in the human vagina were > 128 mcg/ml; therefore these beneficial bacteria are not affected by drug treatment. the exact pharmacologic mode of action of terconazole is uncertain; however, it may exert its antifungal activity by the disruption of normal fungal cell membrane permeability. no resistance to terconazole has developed during successive passages of c. albicans.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility: carcinogenesis: studies to determine the carcinogenic potential of terconazole have not been performed. mutagenicity: terconazole was not mutagenic when tested in vitro for induction of microbial point mutations (ames test), or for inducing cellular transformation, or in vivo for chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells. impairment of fertility: no impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day for a three month period.

How Supplied:

How supplied product: 50090-6299 ndc: 50090-6299-0 20 g in a tube, with applicator

Spl Patient Package Insert:

Terconazole vaginal cream 0.8% patient instructions 3- day therapy filling the applicator: 1. remove the cap from the tube. 2. use the pointed tip on the top of the cap to puncture the seal on the tube. 3. screw the applicator onto the tube. 4. squeeze the tube from the bottom and fill the applicator until the plunger stops. 5. unscrew the applicator from the tube. using the applicator: 1. lie on your back with your knees drawn up toward your chest. 2. holding the applicator by the ribbed end of the barrel, insert the filled applicator into the vagina as far as it will comfortably go . 3. slowly press the plunger of the applicator to release the cream into the vagina. 4. remove the applicator from the vagina. 5. apply one applicatorful each night for as many days at bedtime, as directed by your doctor. cleaning the applicator: after each use, you should thoroughly clean the applicator by following the procedure below: 1. pull the plunger out of the barrel. 2. wash the pieces with lukew
arm, soapy water, and dry them thoroughly. 3. put the applicator back together by gently pushing the plunger into the barrel as far as it will go. note: store at 20°c to 25°c (68°f to 77°f), excursions permitted 15°c to 30°c (59°f to 86°f). [see usp controlled room temperature]. see end flap for lot number and expiration date. a word about yeast infections why do yeast infections occur? yeast infections are caused by an organism called candida (kan di duh). it may be present in small and harmless amounts in the mouth, digestive tract, and vagina. sometimes the natural balance of the vagina becomes upset. this may lead to rapid growth of candida , which results in a yeast infection. symptoms of a yeast infection include itching, burning, redness, and an abnormal discharge. your doctor can make the diagnosis of a yeast infection by evaluating your symptoms and looking at a sample of the discharge under the microscope. how can i prevent yeast infections? certain factors may increase your chance of developing a yeast infection. these factors don't actually cause the problem, but they may create a situation that allows the yeast to grow rapidly. • clothing: tight jeans, nylon underwear, pantyhose, and wet bathing suits can hold in heat and moisture (two conditions in which yeast organisms thrive). looser pants or skirts, 100% cotton underwear, and stockings may help avoid this problem. • diet: cutting down on sweets, milk products, and artificial sweeteners may reduce the risk of yeast infections. • antibiotics: antibiotics work by eliminating disease-causing organisms. while they are helpful in curing other problems, antibiotics may lead to an overgrowth of candida in the vagina. • pregnancy: hormonal changes in the body during pregnancy encourage the growth of yeast. this is a very common time for an infection to occur. until the baby is born, it may be hard to completely eliminate yeast infections. if you believe you are pregnant, tell your doctor. • menstruation: sometimes monthly changes in hormone levels may lead to yeast infections. • diabetes: in addition to heat and moisture, yeast thrives on sugar. because diabetics often have sugar in their urine, their vaginas are rich in this substance. careful control of diabetes may help prevent yeast infections. controlling these factors can help eliminate yeast infections and may prevent them from coming back. some other helpful tips: 1. for best results, be sure to use the medication as prescribed by your doctor, even if you feel better very quickly. 2. avoid sexual intercourse, if your doctor advises you to do so. 3. if your partner has any penile itching, redness, or discomfort, he should consult his physician and mention that you are being treated for a yeast infection. 4. you can use the medication even if you are having your menstrual period. however, you should not use tampons because they may absorb the medication. instead, use external pads or napkins until you have finished your medication. you may also wish to wear a sanitary napkin if the vaginal medication leaks. 5. dry the genital area thoroughly after showering, bathing, or swimming. change out of a wet bathing suit or damp exercise clothes as soon as possible. a dry environment is less likely to encourage the growth of yeast. 6. wipe from front to rear (away from the vagina) after a bowel movement. 7. don't douche unless your doctor specifically tells you to do so. douching may disturb the vaginal balance. 8. don't scratch if you can help it. scratching can cause more irritation and spread the infection. 9. discuss with your physician any medication you are already taking. certain types of medication can make your vagina more susceptible to infection. 10. eat nutritious meals to promote your general health. e. fougera & co. a division of fougera pharmaceuticals inc. melville, new york 11747 46270465a r05/2020 figure figure figure figure

Package Label Principal Display Panel:

Terconazole cream label image


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.